Skip to main content
Top
Published in: Clinical Rheumatology 1/2016

01-01-2016 | Case Based Review

Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature

Authors: Sepideh Faez, Ann-Marie Lobo, Sebastian H. Unizony, John H. Stone, George N. Papaliodis, Lucia Sobrin

Published in: Clinical Rheumatology | Issue 1/2016

Login to get access

Abstract

Scleritis and uveitis are potentially blinding conditions that can be associated with systemic inflammatory diseases. Polymyalgia rheumatica (PMR) is a common rheumatic disorder of the elderly of uncertain etiology. Although there are a few published reports of scleritis and uveitis in PMR patients, the association of PMR to ocular inflammation has not been well established. The aim of this study is to report a series of PMR patients with scleritis and/or uveitis and review the prior published reports of this potential association. We retrospectively reviewed the medical charts of patients with PMR and scleritis or uveitis who were examined in the Ocular Immunology Service of Massachusetts Eye and Ear Infirmary. We also performed a systematic literature search (PubMed; January 1990 until January 2014) to identify earlier published reports. Seven PMR patients with ocular inflammatory disease (OID) were included in our study: two with scleritis, three with anterior uveitis, and two with panuveitis. The onset of PMR preceded the occurrence of OID in six patients, and in one patient uveitis developed 2 months prior to PMR. Five patients demonstrated a temporal association between flares of PMR and OID. In four patients, OID flares developed during tapering of systemic prednisone prescribed for PMR. Four of the five patients who had relapsing PMR had recurrent or persistent uveitis over the course of follow-up. PMR may be associated with both scleritis and uveitis and should be considered as a possible underlying cause of OID.
Literature
1.
go back to reference Hamideh F, Prete PE (2001) Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum 30(4):217–241PubMedCrossRef Hamideh F, Prete PE (2001) Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum 30(4):217–241PubMedCrossRef
2.
go back to reference McCluskey P, Powell RJ (2004) The eye in systemic inflammatory diseases. Lancet 364(9451):2125–2133PubMedCrossRef McCluskey P, Powell RJ (2004) The eye in systemic inflammatory diseases. Lancet 364(9451):2125–2133PubMedCrossRef
3.
go back to reference Doran MF, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE (2002) Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 29(8):1694–1697PubMed Doran MF, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE (2002) Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 29(8):1694–1697PubMed
4.
go back to reference Soriano A, Landolfi R, Manna R (2012) Polymyalgia rheumatica in 2011. Best Pract Res Clin Rheumatol 26(1):91–104PubMedCrossRef Soriano A, Landolfi R, Manna R (2012) Polymyalgia rheumatica in 2011. Best Pract Res Clin Rheumatol 26(1):91–104PubMedCrossRef
5.
go back to reference Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347(4):261–271PubMedCrossRef Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347(4):261–271PubMedCrossRef
6.
go back to reference Bandini F, Benedetti L, Ceppa P, Corallo G (2005) Uveitis as a presenting sign of giant cell arteritis. J Neuroophthalmol 25(3):247–248PubMedCrossRef Bandini F, Benedetti L, Ceppa P, Corallo G (2005) Uveitis as a presenting sign of giant cell arteritis. J Neuroophthalmol 25(3):247–248PubMedCrossRef
7.
8.
go back to reference Rajesh CV, Cole M (2000) Panuveitis as a presenting feature of giant cell arteritis. Br J Ophthalmol 84(3):340PubMed Rajesh CV, Cole M (2000) Panuveitis as a presenting feature of giant cell arteritis. Br J Ophthalmol 84(3):340PubMed
9.
go back to reference Coppeto JR, Monteiro ML, Sciarra R (1985) Giant-cell arteritis with bilateral uveitic glaucoma. Ann Ophthalmol 17(5):299–302PubMed Coppeto JR, Monteiro ML, Sciarra R (1985) Giant-cell arteritis with bilateral uveitic glaucoma. Ann Ophthalmol 17(5):299–302PubMed
10.
go back to reference Long RG, Friedmann AI, James DG (1976) Scleritis and temporal arteritis. Postgrad Medl J 52(613):689–692CrossRef Long RG, Friedmann AI, James DG (1976) Scleritis and temporal arteritis. Postgrad Medl J 52(613):689–692CrossRef
13.
go back to reference Smeeth L, Cook C, Hall AJ (2006) Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 65(8):1093–1098PubMedPubMedCentralCrossRef Smeeth L, Cook C, Hall AJ (2006) Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 65(8):1093–1098PubMedPubMedCentralCrossRef
14.
go back to reference Takano T, Okisaka S, Hamanaka T, Ishida T, Hara J (1990) A case of necrotizing scleritis with angiitis of papilla. Nihon Ganka Gakkai Zasshi 94(4):424–431PubMed Takano T, Okisaka S, Hamanaka T, Ishida T, Hara J (1990) A case of necrotizing scleritis with angiitis of papilla. Nihon Ganka Gakkai Zasshi 94(4):424–431PubMed
15.
16.
go back to reference Simmons IG, Kritzinger EE, Murray PI (1997) Posterior scleritis and polymyalgia rheumatica. Eye (Lond) 11(Pt 5):727–728CrossRef Simmons IG, Kritzinger EE, Murray PI (1997) Posterior scleritis and polymyalgia rheumatica. Eye (Lond) 11(Pt 5):727–728CrossRef
17.
go back to reference Tsuda H, Tanaka K, Kishida S (2011) Anterior uveitis as an initial manifestation of polymyalgia rheumatica. Case Rep Med 2011:621241PubMedPubMedCentral Tsuda H, Tanaka K, Kishida S (2011) Anterior uveitis as an initial manifestation of polymyalgia rheumatica. Case Rep Med 2011:621241PubMedPubMedCentral
18.
go back to reference Asensio Sanchez VM, Botella Oltra G, Carrasco E (2004) Biphosphonates and intraocular inflammation. Arch Soc Esp Oftalmol 79(2):85–87PubMedCrossRef Asensio Sanchez VM, Botella Oltra G, Carrasco E (2004) Biphosphonates and intraocular inflammation. Arch Soc Esp Oftalmol 79(2):85–87PubMedCrossRef
19.
go back to reference Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM (1993) Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 36(9):1286–1294PubMedCrossRef Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM (1993) Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 36(9):1286–1294PubMedCrossRef
20.
go back to reference Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ (1999) Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 159(6):577–584PubMedCrossRef Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ (1999) Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 159(6):577–584PubMedCrossRef
21.
go back to reference Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D, Bajocchi G, Vinceti M, Catanoso MG, Pulsatelli L, Meliconi R, Boiardi L (2005) Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 53(1):33–38PubMedCrossRef Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D, Bajocchi G, Vinceti M, Catanoso MG, Pulsatelli L, Meliconi R, Boiardi L (2005) Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 53(1):33–38PubMedCrossRef
22.
go back to reference Alvarez-Rodriguez L, Lopez-Hoyos M, Mata C, Marin MJ, Calvo-Alen J, Blanco R, Aurrecoechea E, Ruiz-Soto M, Martinez-Taboada VM (2010) Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 69(1):263–269PubMedCrossRef Alvarez-Rodriguez L, Lopez-Hoyos M, Mata C, Marin MJ, Calvo-Alen J, Blanco R, Aurrecoechea E, Ruiz-Soto M, Martinez-Taboada VM (2010) Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 69(1):263–269PubMedCrossRef
23.
go back to reference Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE (2003) Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 33(1):38–48PubMedCrossRef Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE (2003) Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 33(1):38–48PubMedCrossRef
24.
go back to reference Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, Macchioni P, Bajocchi G, Catanoso MG, Pulsatelli L, Consonni D, Salvarani C (2006) Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 33(4):703–708PubMed Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, Macchioni P, Bajocchi G, Catanoso MG, Pulsatelli L, Consonni D, Salvarani C (2006) Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 33(4):703–708PubMed
26.
go back to reference Kramer M, Monselise Y, Bahar I, Cohen Y, Weinberger D, Goldenberg-Cohen N (2007) Serum cytokine levels in active uveitis and remission. Curr Eye Res 32(7–8):669–675PubMedCrossRef Kramer M, Monselise Y, Bahar I, Cohen Y, Weinberger D, Goldenberg-Cohen N (2007) Serum cytokine levels in active uveitis and remission. Curr Eye Res 32(7–8):669–675PubMedCrossRef
27.
go back to reference Perez VL, Papaliodis GN, Chu D, Anzaar F, Christen W, Foster CS (2004) Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm 12(3):193–201PubMedCrossRef Perez VL, Papaliodis GN, Chu D, Anzaar F, Christen W, Foster CS (2004) Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm 12(3):193–201PubMedCrossRef
28.
go back to reference de Boer JH, van Haren MA, de Vries-Knoppert WA, Baarsma GS, de Jong PV, Postema FJ, Rademakers AJ, Kijlstra A (1992) Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Curr Eye Res 11(Suppl):181–186PubMedCrossRef de Boer JH, van Haren MA, de Vries-Knoppert WA, Baarsma GS, de Jong PV, Postema FJ, Rademakers AJ, Kijlstra A (1992) Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Curr Eye Res 11(Suppl):181–186PubMedCrossRef
29.
go back to reference Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13(6):711–718PubMedCrossRef Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13(6):711–718PubMedCrossRef
30.
go back to reference Yoshimura T, Sonoda KH, Miyazaki Y, Iwakura Y, Ishibashi T, Yoshimura A, Yoshida H (2008) Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int Immunol 20(2):209–214PubMedCrossRef Yoshimura T, Sonoda KH, Miyazaki Y, Iwakura Y, Ishibashi T, Yoshimura A, Yoshida H (2008) Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int Immunol 20(2):209–214PubMedCrossRef
31.
go back to reference Weyand CM, Younge BR, Goronzy JJ (2011) IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 23(1):43–49PubMedPubMedCentralCrossRef Weyand CM, Younge BR, Goronzy JJ (2011) IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 23(1):43–49PubMedPubMedCentralCrossRef
32.
go back to reference Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441(7090):231–234PubMedCrossRef Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441(7090):231–234PubMedCrossRef
33.
go back to reference Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238PubMedCrossRef Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235–238PubMedCrossRef
34.
go back to reference Haruta H, Ohguro N, Fujimoto M, Hohki S, Terabe F, Serada S, Nomura S, Nishida K, Kishimoto T, Naka T (2011) Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 52(6):3264–3271PubMedCrossRef Haruta H, Ohguro N, Fujimoto M, Hohki S, Terabe F, Serada S, Nomura S, Nishida K, Kishimoto T, Naka T (2011) Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 52(6):3264–3271PubMedCrossRef
35.
go back to reference Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, Stone JR, Stone JH (2012) Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 64(11):1720–1729PubMedCrossRef Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, Stone JR, Stone JH (2012) Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 64(11):1720–1729PubMedCrossRef
36.
go back to reference Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R, Salvarani C (2013) Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum 43(1):113–118PubMedCrossRef Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R, Salvarani C (2013) Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum 43(1):113–118PubMedCrossRef
37.
go back to reference Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A (2011) Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 19(5):382–383PubMedCrossRef Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A (2011) Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 19(5):382–383PubMedCrossRef
38.
go back to reference Tappeiner C, Heinz C, Ganser G, Heiligenhaus A (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39(6):1294–1295PubMedCrossRef Tappeiner C, Heinz C, Ganser G, Heiligenhaus A (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39(6):1294–1295PubMedCrossRef
39.
go back to reference Moosig F, Czech N, Mehl C, Henze E, Zeuner RA, Kneba M, Schroder JO (2004) Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann Rheum Dis 63(7):870–873PubMedPubMedCentralCrossRef Moosig F, Czech N, Mehl C, Henze E, Zeuner RA, Kneba M, Schroder JO (2004) Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann Rheum Dis 63(7):870–873PubMedPubMedCentralCrossRef
40.
go back to reference Blockmans D, Maes A, Stroobants S, Nuyts J, Bormans G, Knockaert D, Bobbaers H, Mortelmans L (1999) New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxford) 38(5):444–447CrossRef Blockmans D, Maes A, Stroobants S, Nuyts J, Bormans G, Knockaert D, Bobbaers H, Mortelmans L (1999) New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxford) 38(5):444–447CrossRef
41.
go back to reference Hayreh SS, Podhajsky PA, Zimmerman B (1998) Ocular manifestations of giant cell arteritis. Am J Ophthalmol 125(4):509–520PubMedCrossRef Hayreh SS, Podhajsky PA, Zimmerman B (1998) Ocular manifestations of giant cell arteritis. Am J Ophthalmol 125(4):509–520PubMedCrossRef
42.
go back to reference Fong LP, Sainz de la Maza M, Rice BA, Kupferman AE, Foster CS (1991) Immunopathology of scleritis. Ophthalmology 98(4):472–479PubMedCrossRef Fong LP, Sainz de la Maza M, Rice BA, Kupferman AE, Foster CS (1991) Immunopathology of scleritis. Ophthalmology 98(4):472–479PubMedCrossRef
43.
go back to reference Mackie SL, Pease CT (2013) Diagnosis and management of giant cell arteritis and polymyalgia rheumatica: challenges, controversies and practical tips. Postgrad Med J 89(1051):284–292PubMedCrossRef Mackie SL, Pease CT (2013) Diagnosis and management of giant cell arteritis and polymyalgia rheumatica: challenges, controversies and practical tips. Postgrad Med J 89(1051):284–292PubMedCrossRef
44.
go back to reference Darrell RW, Wagener HP, Kurland LT (1962) Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 68:502–514PubMedCrossRef Darrell RW, Wagener HP, Kurland LT (1962) Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 68:502–514PubMedCrossRef
45.
go back to reference Rothova A, Buitenhuis HJ, Meenken C, Brinkman CJ, Linssen A, Alberts C, Luyendijk L, Kijlstra A (1992) Uveitis and systemic disease. Br J Ophthalmol 76(3):137–141PubMedPubMedCentralCrossRef Rothova A, Buitenhuis HJ, Meenken C, Brinkman CJ, Linssen A, Alberts C, Luyendijk L, Kijlstra A (1992) Uveitis and systemic disease. Br J Ophthalmol 76(3):137–141PubMedPubMedCentralCrossRef
46.
go back to reference Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80(4):332–336PubMedPubMedCentralCrossRef Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80(4):332–336PubMedPubMedCentralCrossRef
47.
go back to reference Saari KM, Paivonsalo-Hietanen T, Vaahtoranta-Lehtonen H, Tuominen J, Sillanpaa M (1995) Epidemiology of endogenous uveitis in south-western Finland. Acta Ophthalmol Scand 73(4):345–349PubMedCrossRef Saari KM, Paivonsalo-Hietanen T, Vaahtoranta-Lehtonen H, Tuominen J, Sillanpaa M (1995) Epidemiology of endogenous uveitis in south-western Finland. Acta Ophthalmol Scand 73(4):345–349PubMedCrossRef
48.
go back to reference Boyd M, Specks U, Finkielman JD (2010) Accuracy of the ICD-9 code for identification of patients with Wegener's granulomatosis. J Rheumatol 37(2):474PubMedCrossRef Boyd M, Specks U, Finkielman JD (2010) Accuracy of the ICD-9 code for identification of patients with Wegener's granulomatosis. J Rheumatol 37(2):474PubMedCrossRef
Metadata
Title
Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature
Authors
Sepideh Faez
Ann-Marie Lobo
Sebastian H. Unizony
John H. Stone
George N. Papaliodis
Lucia Sobrin
Publication date
01-01-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 1/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2558-6

Other articles of this Issue 1/2016

Clinical Rheumatology 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.